A biopharmaceutical company, Neuralstem develops nervous system therapies derived from neural stem cell technology.
Here are six takeaways:
1. NSI-566 represents the company’s lead stem cell therapy candidate.
2. University of California San Diego serves as the study site, and just added a new cohort of four patients.
3. The four new patients all have AIS-A complete, quadriplegic, cervical injuries involving C5-C7 cord.
4. The patients suffered the injury one to two years before undergoing stem cell treatment.
5. The treatment involves six injections of NSI-566 into the spinal cord’s affected area.
6. UCSD researchers are analyzing long-term safety data from the study’s first cohort on chronic complete thoracic injuries.
More articles on spine:
Dr. Scott Blumenthal performs 1st US herniated disc surgery with Anchor Orthopaedics tissue kit — 5 highlights
Private practice in spine surgery: Key challenges & opportunities from Dr. Scott Blumenthal
Cervical Spine Research Society names 5 new officers
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
